title: Predicting the effect of D,L-sotalol on ventricular tachycardia inducibility from the RR variability response.
abstract: OBJECTIVE
  To find a rapid way of identifying non-responders to D, L-sotalol in patients with ventricular tachycardia.
  
  
  METHODS
  Programmed ventricular stimulation and RR variability were studied in the control state and 10 days after treatment with 160 to 320 mg of D,L-sotalol in 36 consecutive patients with ventricular tachycardia.
  
  
  RESULTS
  In 14 patients (group I) D,L-sotalol suppressed ventricular tachycardia inducibility. In 22 patients (group II) sustained ventricular tachycardia remained inducible during D,L-sotalol treatment. The ventricular tachycardia rate was slowed in eight patients and unchanged or accelerated in 14. At baseline, heart rate variability was similar in both groups. During treatment with D,L-sotalol, variables reflecting parasympathetic activity (pNN50, rMSSD, and high frequency amplitude (HF)) increased in both groups: HF increased from (mean (SD)) 75 (68) to 146 (134) in group I (p < 0.05) and from 60 (49) to 125 (79) in group II (p < 0.05). Other variables were unchanged in group I. In group II, the variables associated with sympathetic activity (coefficient of variance (CV), ratio of low frequency amplitude (LF) to HF) decreased significantly: CV decreased from 13 (4) to 9 (2) (p < 0. 001) and LF/HF from 4.74 (3.02) to 3.00 (2.02) (p < 0.05).
  
  
  CONCLUSIONS
  The beta blocking effect of D,L-sotalol produced a significant improvement over control values in indices of parasympathetic tone in all treated patients. However, the heart rate variability indices related to sympathetic activity were decreased only in non-responders. This effect of D,L-sotalol on heart rate variability could help detect non-responders to the drug and avoid an electrophysiological study.
authors.affiliation: Cardiology, CHU Brabois, 54500 Vandoeuvre, France.
authors.forename: B
authors.initials: B
authors.lastname: Brembilla-Perrot
authors.forename: P
authors.initials: P
authors.lastname: Houriez
authors.forename: O
authors.initials: O
authors.lastname: Claudon
authors.forename: J P
authors.initials: JP
authors.lastname: Preiss
authors.forename: D
authors.initials: D
authors.lastname: Beurrier
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D004558:Electric Stimulation; D015716:Electrocardiography, Ambulatory; D005260:Female; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D013015:Sotalol / Q000627:therapeutic use*; D017180:Tachycardia, Ventricular / Q000503:physiopathology / Q000517:prevention & control*; D017211:Treatment Failure
chemical_list: D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D013015:Sotalol